From a horizontal accumulation phase, the timing seems good to buy shares in Chemours Co and to get ahead of a break-out on the upside of the congestion area. Investors have an opportunity to buy the stock and target the $ 60.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
The group's high margin levels account for strong profits.
With a P/E ratio at 14.52 for the current year and 12.61 for next year, earnings multiples are highly attractive compared with competitors.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 36 USD
Stock prices approach a strong long-term resistance in weekly data at USD 57.23.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.